PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.76
+0.09 (+0.21%)
At close: 4:00PM EDT

43.76 0.00 (0.00%)
After hours: 5:40PM EDT

Stock chart is not supported by your current browser
Previous Close43.67
Open43.69
Bid43.82 x 4000
Ask43.94 x 800
Day's Range43.47 - 43.90
52 Week Range36.00 - 46.47
Volume23,335,839
Avg. Volume21,734,607
Market Cap242.947B
Beta (3Y Monthly)0.43
PE Ratio (TTM)22.48
EPS (TTM)1.95
Earnings DateJul 30, 2019
Forward Dividend & Yield1.44 (3.30%)
Ex-Dividend Date2019-05-09
1y Target Est45.57
Trade prices are not sourced from all markets
  • Comparing PFE’s and BMY’s Revenue Trajectory
    Market Realist39 minutes ago

    Comparing PFE’s and BMY’s Revenue Trajectory

    Pfizer (PFE) has guided for its revenue falling 1.2% YoY (year-over-year) to $52.0 billion–$54.0 billion in fiscal 2019, whereas analysts expect the company’s revenue to fall 0.55% to $53.35 billion.

  • Why These Innovative Biotech ETFs Soaring
    Zacks2 hours ago

    Why These Innovative Biotech ETFs Soaring

    Strong M&A activity has sent shares of many small, innovative biotech companies surging

  • This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data
    Investor's Business Daily2 hours ago

    This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data

    Sarepta Therapeutics will face a "whale" of an overhang Friday when Dow Jones stock Pfizer unveils the results of its gene therapy in Duchenne muscular dystrophy, an analyst said Monday.

  • What Analysts Recommend for Pfizer and Bristol-Myers Squibb
    Market Realist2 hours ago

    What Analysts Recommend for Pfizer and Bristol-Myers Squibb

    This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

  • Eldorado to Buy Caesars
    Zacks7 hours ago

    Eldorado to Buy Caesars

    Eldorado to Buy Caesars

  • BioMarin Gets $15M From Pfizer on Talzenna's European Nod
    Zacks7 hours ago

    BioMarin Gets $15M From Pfizer on Talzenna's European Nod

    BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

  • U.S. Senate Takes on Big Tech, Plus "Merger Monday"
    Zacks8 hours ago

    U.S. Senate Takes on Big Tech, Plus "Merger Monday"

    Eldorado Resorts (ELR) has agreed to buy Caesars (CZR) for $8.6 billion, and a bipartisan bill in the Senate holds Big Tech accountable for monetized user data.

  • Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
    Zacks10 hours ago

    Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

    Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

  • These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
    Motley Foolyesterday

    These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

    These stocks were huge winners last week. But can their momentum continue?

  • Is There An Opportunity With Pfizer Inc.'s (NYSE:PFE) 50% Undervaluation?
    Simply Wall St.yesterday

    Is There An Opportunity With Pfizer Inc.'s (NYSE:PFE) 50% Undervaluation?

    Does the June share price for Pfizer Inc. (NYSE:PFE) reflect what it's really worth? Today, we will estimate the...

  • Do Institutions Own Shares In Pfizer Inc. (NYSE:PFE)?
    Simply Wall St.yesterday

    Do Institutions Own Shares In Pfizer Inc. (NYSE:PFE)?

    Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. Insiders often own a...

  • Benzinga2 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

    Biotech stocks came made upward moves last week after a rangebound period.  Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...

  • Business Wire2 days ago

    PFIZER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Pfizer Inc. - PFE

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Pfizer Inc. (PFE). On August 10, 2017 the Company disclosed that the U.S. Department of Justice was investigating its wholly-owned subsidiary, Greenstone, advising investors that “[w]e believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry.” Recently, the Company was among those sued in a wide-ranging lawsuit brought by 44 state attorneys general alleging an illegal conspiracy to inflate prices of more than 100 generic drugs, sometimes by more than 1,000%, and stifle competition.

  • Amag’s plan to bypass female libido drug pitfalls? Social media.
    American City Business Journals3 days ago

    Amag’s plan to bypass female libido drug pitfalls? Social media.

    Amag Pharmaceuticals Inc. has received regulatory approval to begin selling Vyleesi, a drug designed to address hypoactive sexual disorder, a condition in which causes low sexual desire and distress in an estimated one in 10 women.

  • Dow Jones Today: A Typical Summer Friday
    InvestorPlace3 days ago

    Dow Jones Today: A Typical Summer Friday

    Interestingly, June 21 marks the official start of summer, and the summer months often bring lethargy in the equity markets, particularly on Fridays. That was the case today as stocks, broadly speaking, were mostly listless.Source: Shutterstock To close the week, the S&P 500 fell a scant 0.13%, and the Nasdaq Composite lost 0.24%. The Dow Jones Industrial Average also lost 0.13%. Long-term investors can find some solace on the day of the summer solstice with an article in Barron's today indicating Dow 30,000 could arrive sooner than expected."To stick with our 2025 forecast now would be to suggest that stocks over the next 5½ years will climb just 2.1% a year, plus dividends," according to Barron's. "It's possible, but pessimistic. The Dow could reach 30,000 much sooner than 2025."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe article indicates it is possible the Dow sees 30,000 sometime in 2021, a bullish forecast considering the blue-chip index closed around 26,800 today.That is a long-term forecast. Over the near-term, the Federal Reserve will likely dominate the conversation and that is not surprising. For investors hoping for rate cut this year, good news: Fed funds traders bet on such a move in record fashion this week, according to CNBC. Some Mild WinnersBy the end of the day, just two of the 30 Dow Jones stocks were sporting gains of 1% or more. The clear powerhouse was UnitedHealth Group (NYSE:UNH), which gained 1.82% on new that it is acquiring health-care payments provider Equian LLC for $3.2 billion. * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 That is a drop in the bucket for UnitedHealth, which has a market capitalization of $240 billion and a stellar return for Equian's private equity owner New Mountain, which purchased the company four years ago for just $225 million.Defensive names have been getting some attention here in recent weeks and with good reason. Today, Dow component Walmart (NYSE:WMT), on essentially no news to merit a move like this, jump 0.73% to hit an all-time high. The largest U.S. retailer is up almost 20% year-to-date.Pharmaceuticals giant Pfizer (NYSE:PFE) added 0.88% after the European Commission approved the company's TALZENNA treatment for breast cancer patients. The U.S. Food and Drug Administration (FDA) approved the treatment last October."We are thrilled that we can now offer these patients in Europe, who are often diagnosed at a younger age and have limited treatment options, an effective, once-daily, alternative treatment to chemotherapy," said Pfizer in a statement.Staying in the blue-chip pharmaceuticals space, Merck & Co. (NYSE:MRK) closed modestly lower, but three analysts raised price targets on the stock to $90, $95 and $96, respectively. In either case, that is some decent upside from Merck's Friday close around $84.50. Bottom Line on the Dow Jones TodayWith all the talk about a potential rate cut, investors should not forget that second-quarter earnings season will soon be here. While glum earnings may be baked into the market at current levels, investors should still expect some less-than-positive sentiment around the second-quarter numbers."As of today, the estimated earnings decline for the second quarter for the S&P 500 stands at -2.6%," said FactSet in a note out Friday. "If -2.6% is the actual earnings decline for the quarter, it will mark the first time the index has reported two straight quarters of year-over-year declines in earnings since Q1 2016 and Q2 2016. It will also mark the largest year-over-year decline in earnings since Q2 2016 (-3.2%)."Unfortunately, the same note indicates analysts are ratcheting down third-quarter estimates with the energy and technology sectors looking like the worst offenders.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post Dow Jones Today: A Typical Summer Friday appeared first on InvestorPlace.

  • Benzinga3 days ago

    Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

    Pfizer (NYSE:PFE) has received approval from the European Commission for its TALZENNA a breast cancer drug. This approval follows the medicine's approval by the U.S. Food and Drug Administration in October 2018. "Today's approval of TALZENNA for certain patients with advanced-stage breast cancer and an inherited BRCA mutation is the latest example of our successful precision medicine approach to drug development," said Andreas Penk, regional president, Oncology international developed markets at Pfizer in a statement.

  • Business Wire3 days ago

    European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

    Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer

  • Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
    Zacks3 days ago

    Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

    The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

  • Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
    Zacks3 days ago

    Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up

    Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.

  • Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
    Zacks3 days ago

    Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

    Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

  • Motley Fool4 days ago

    Is Pfizer Overpaying for Array Biopharma?

    The $11.5 billion acquisition price values the target at a 62% premium.

  • Stock Market News For Jun 20, 2019
    Zacks4 days ago

    Stock Market News For Jun 20, 2019

    Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.

  • Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years
    Investor's Business Daily5 days ago

    Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years

    Dow Jones component Pfizer could become a leader in colon cancer treatment with its looming $11.4 billion acquisition of biotech company Array BioPharma, an analyst said Wednesday.

  • GSK kicks off sale of $1.2 billion consumer health drugs: sources
    Reuters5 days ago

    GSK kicks off sale of $1.2 billion consumer health drugs: sources

    GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.